Antibody-Drug Conjugate (ADC) Research in Ophthalmology--a Review.

Shen, Jie; Attar, Mayssa

Shen, Jie; Attar, Mayssa.

Affiliation

Shen J; Department of Pharmacokinetics, Dynamics and Disposition, Allergan, Irvine, California, 92612, USA. shen_jie@allergan.com.
Attar M; Allergan, Inc., 2525 Dupont Drive, Irvine, California, 92612, USA. shen_jie@allergan.com.

Pharm Res ; 32(11): 3572-6, 2015 Nov.

Article in En | MEDLINE | ID: mdl-26058945

Subject(s)

Antibodies, Monoclonal/therapeutic use; Capsule Opacification/drug therapy; Choroidal Neovascularization/drug therapy; Immunoconjugates/therapeutic use; Vitreoretinopathy, Proliferative/drug therapy; Animals; Antibodies, Monoclonal/administration & dosage; Cell Proliferation/drug effects; Clinical Trials as Topic; Humans; Immunoconjugates/administration & dosage; Molecular Targeted Therapy; Vascular Endothelial Growth Factor A/antagonists & inhibitors

Key words

antibody-drug conjugate; choroidal neovascularization; ocular; posterior lens capsule opacification; proliferative vitreoretinopathy; safety

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vitreoretinopathy, Proliferative / Immunoconjugates / Choroidal Neovascularization / Capsule Opacification / Antibodies, Monoclonal Type of study: Risk_factors_studies Limits: Animals / Humans Language: En Journal: Pharm Res Year: 2015 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google